Dainippon Sumitomo Pharma (DSP) has licensed Japanese rights to develop and commercialise Edison Pharmaceuticals’ redox-directed drug candidates EPI-743 and EPI-589. EPI-743 is currently being studied in a Phase IIb trial in patients with Leigh syndrome, a lethal and progressive mitochondrial disease for which there are no approved treatments. While DSP will be responsible for advancing EPI-743 in Japan, with an initial focus on orphan paediatric mitochondrial disease, the two companies will collaborate on the research and development of EPI-589, with a focus on adult CNS disease.